Stuart Levin, MD
Internal Medicine · Raleigh, NCNPI 1225023807
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Abbott at 59.7% of the total. 2025 is the largest year on record at $114, 9.1 times the $13 reported in 2021.
Across 11 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$134
- Dexcom, Inc.$21
- E.r. Squibb & Sons, L.L.C.$20
- Grifols USA, LLC$18
- Phadia US Inc.$15
- Echosens North America, Inc.$15
What the payments were for
- Food & beverage$224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $134 |
| Dexcom, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Grifols USA, LLC | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Echosens North America, Inc. | 1 | $15 |
How this compares
$224 in reported general payments places this provider in the 55th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $105,519 |
| JardianceEmpagliflozin | 76 | $88,942 |
| OzempicSemaglutide | 71 | $82,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $39,015 |
| JanuviaSitagliptin Phosphate | 25 | $25,080 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $18,944 |
| XareltoRivaroxaban | 11 | $17,159 |
| WegovySemaglutide | 12 | $16,577 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $16,013 |
| Spiriva HandihalerTiotropium Bromide | 19 | $14,806 |
| LinzessLinaclotide | 17 | $12,266 |
| RybelsusSemaglutide | 13 | $10,675 |
| VascepaIcosapent Ethyl | 16 | $9,430 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,330 |
| Fluticasone Propionate HfaFluticasone Propionate | 24 | $8,289 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Raleigh
- Bhakti PaulRaleigh$536K
- Christina CraterRaleigh$330K
- Charles CookRaleigh$228K
- Anthony AzziRaleigh$81K
- Dishita PandyaRaleigh$71K
- Afreen ShariffRaleigh$66K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Mary KlotmanDurham$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.